Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Open Access
- 6 August 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (1) , 116-121
Abstract
Background No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor, abundant in meningiomas. Methods This was a prospective, multicenter, investigator-initiated single-arm phase II trial. The primary cohort enrolled patients with surgery and radiation-refractory recurrent World Health Organization (WHO) grades II–III meningioma. An exploratory cohort enrolled patients with WHO grade I meningioma, hemangiopericytoma, or hemangioblastoma. Sunitinib was administered at 50 mg/d for days 1–28 of every 42-day cycle. The primary endpoint was the rate of 6-month progression-free survival (PFS6), with secondary endpoints of radiographic response rate, safety, PFS, and overall survival. Exploratory objectives include analysis of tumoral molecular markers and MR perfusion imaging. Results Thirty-six patients with high-grade meningioma (30 atypical and 6 anaplastic) were enrolled. Patients were heavily pretreated (median number of 5 recurrences, range 2–10). PFS6 rate was 42%, meeting the primary endpoint. Median PFS was 5.2 months (95% CI: 2.8–8.3 mo), and median overall survival was 24.6 months (95% CI: 16.5–38.4 mo). Thirteen patients enrolled in the exploratory cohort. Overall toxicity included 1 grade 5 intratumoral hemorrhage, 2 grade 3 and 1 grade 4 CNS/intratumoral hemorrhages, 1 grade 3 and 1 grade 4 thrombotic microangiopathy, and 1 grade 3 gastrointestinal perforation. Expression of VEGFR2 predicted PFS of a median of 1.4 months in VEGFR2-negative patients versus 6.4 months in VEGFR2-positive patients (P = .005). Conclusion Sunitinib is active in recurrent atypical/malignant meningioma patients. A randomized trial should be performed.Keywords
This publication has 35 references indexed in Scilit:
- Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective seriesJournal of Neuro-Oncology, 2012
- Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningiomaJournal of Neuro-Oncology, 2011
- Angiogenesis in meningiomasBrain Tumor Pathology, 2011
- Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytomaNeuro-Oncology, 2011
- A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasNeuro-Oncology, 2009
- Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Neuro-Oncology, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- The Treatment of Recurrent Unresectable and Malignant Meningiomas with Interferon Alpha-2BNeurosurgery, 1997
- A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group studyJournal of Neuro-Oncology, 1993
- Antiestrogenic therapy of meningiomas—a pilot studySurgical Neurology, 1985